574 related articles for article (PubMed ID: 15270726)
21. In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses.
Halstead ES; Mueller YM; Altman JD; Katsikis PD
Nat Immunol; 2002 Jun; 3(6):536-41. PubMed ID: 12021777
[TBL] [Abstract][Full Text] [Related]
22. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses.
Tan JT; Whitmire JK; Ahmed R; Pearson TC; Larsen CP
J Immunol; 1999 Nov; 163(9):4859-68. PubMed ID: 10528187
[TBL] [Abstract][Full Text] [Related]
23. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer.
Martinet O; Divino CM; Zang Y; Gan Y; Mandeli J; Thung S; Pan PY; Chen SH
Gene Ther; 2002 Jun; 9(12):786-92. PubMed ID: 12040460
[TBL] [Abstract][Full Text] [Related]
24. 4-1BBL coexpression enhances HIV-specific CD8 T cell memory in a poxvirus prime-boost vaccine.
Harrison JM; Bertram EM; Boyle DB; Coupar BE; Ranasinghe C; Ramshaw IA
Vaccine; 2006 Nov; 24(47-48):6867-74. PubMed ID: 17050052
[TBL] [Abstract][Full Text] [Related]
25. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.
Ito F; Li Q; Shreiner AB; Okuyama R; Jure-Kunkel MN; Teitz-Tennenbaum S; Chang AE
Cancer Res; 2004 Nov; 64(22):8411-9. PubMed ID: 15548712
[TBL] [Abstract][Full Text] [Related]
26. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.
Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ
Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855
[TBL] [Abstract][Full Text] [Related]
27. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28.
Hurtado JC; Kim SH; Pollok KE; Lee ZH; Kwon BS
J Immunol; 1995 Oct; 155(7):3360-7. PubMed ID: 7561030
[TBL] [Abstract][Full Text] [Related]
28. During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion.
Hendriks J; Xiao Y; Rossen JW; van der Sluijs KF; Sugamura K; Ishii N; Borst J
J Immunol; 2005 Aug; 175(3):1665-76. PubMed ID: 16034107
[TBL] [Abstract][Full Text] [Related]
29. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?
Croft M
Nat Rev Immunol; 2003 Aug; 3(8):609-20. PubMed ID: 12974476
[TBL] [Abstract][Full Text] [Related]
30. Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines.
Harrop JA; Reddy M; Dede K; Brigham-Burke M; Lyn S; Tan KB; Silverman C; Eichman C; DiPrinzio R; Spampanato J; Porter T; Holmes S; Young PR; Truneh A
J Immunol; 1998 Aug; 161(4):1786-94. PubMed ID: 9712045
[TBL] [Abstract][Full Text] [Related]
31. Role of 4-1BB in immune responses.
Vinay DS; Kwon BS
Semin Immunol; 1998 Dec; 10(6):481-9. PubMed ID: 9826581
[TBL] [Abstract][Full Text] [Related]
32. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death.
Hurtado JC; Kim YJ; Kwon BS
J Immunol; 1997 Mar; 158(6):2600-9. PubMed ID: 9058792
[TBL] [Abstract][Full Text] [Related]
33. Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy.
Sica G; Chen L
Arch Immunol Ther Exp (Warsz); 1999; 47(5):275-9. PubMed ID: 10604232
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy with agonistic anti-CD137: two sides of a coin.
Sun Y; Chen JH; Fu Y
Cell Mol Immunol; 2004 Feb; 1(1):31-6. PubMed ID: 16212918
[TBL] [Abstract][Full Text] [Related]
35. Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo.
Yan X; Johnson BD; Orentas RJ
Immunology; 2004 May; 112(1):105-16. PubMed ID: 15096190
[TBL] [Abstract][Full Text] [Related]
36. Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses.
Lee SW; Park Y; Song A; Cheroutre H; Kwon BS; Croft M
J Immunol; 2006 Oct; 177(7):4464-72. PubMed ID: 16982882
[TBL] [Abstract][Full Text] [Related]
37. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB.
Ye Z; Hellström I; Hayden-Ledbetter M; Dahlin A; Ledbetter JA; Hellström KE
Nat Med; 2002 Apr; 8(4):343-8. PubMed ID: 11927939
[TBL] [Abstract][Full Text] [Related]
38. Contribution of CD30/CD153 but not of CD27/CD70, CD134/OX40L, or CD137/4-1BBL to the optimal induction of protective immunity to Mycobacterium avium.
Flórido M; Borges M; Yagita H; Appelberg R
J Leukoc Biol; 2004 Nov; 76(5):1039-46. PubMed ID: 15316035
[TBL] [Abstract][Full Text] [Related]
39. Novel peptide-based vaccines efficiently prime murine "help"-independent CD8+ T cell responses in the liver.
Dikopoulos N; Riedl P; Schirmbeck R; Reimann J
Hepatology; 2004 Aug; 40(2):300-9. PubMed ID: 15368434
[TBL] [Abstract][Full Text] [Related]
40. 4-1BB triggers IL-13 production from T cells to limit the polarized, Th1-mediated inflammation.
Shin SM; Kim YH; Choi BK; Kwon PM; Lee HW; Kwon BS
J Leukoc Biol; 2007 Jun; 81(6):1455-65. PubMed ID: 17389581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
